Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN

Quinn Opportunity Partners LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 63.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,264 shares of the life sciences company’s stock after selling 62,423 shares during the period. Quinn Opportunity Partners LLC’s holdings in Illumina were worth $3,349,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Quent Capital LLC acquired a new position in Illumina in the 3rd quarter worth about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Illumina during the third quarter valued at about $33,000. Mather Group LLC. acquired a new stake in shares of Illumina during the third quarter valued at about $46,000. Evelyn Partners Investment Management LLP grew its holdings in shares of Illumina by 4,927.3% during the second quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 542 shares during the last quarter. Finally, SJS Investment Consulting Inc. grew its holdings in shares of Illumina by 13,225.0% during the third quarter. SJS Investment Consulting Inc. now owns 533 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 529 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Barclays raised their price objective on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Evercore set a $150.00 price target on shares of Illumina in a research note on Friday, February 6th. Wall Street Zen upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Finally, UBS Group reissued a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus target price of $129.69.

Illumina Stock Performance

NASDAQ:ILMN opened at $118.94 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a 50 day simple moving average of $133.15 and a two-hundred day simple moving average of $119.81. The company has a market capitalization of $18.19 billion, a PE ratio of 21.82, a P/E/G ratio of 2.21 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the company earned $0.95 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.